Brooklyn FI LLC Increases Holdings in Johnson & Johnson $JNJ

Brooklyn FI LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,098 shares of the company’s stock after purchasing an additional 94 shares during the period. Brooklyn FI LLC’s holdings in Johnson & Johnson were worth $320,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Sovran Advisors LLC grew its stake in Johnson & Johnson by 7.2% during the second quarter. Sovran Advisors LLC now owns 6,323 shares of the company’s stock valued at $985,000 after acquiring an additional 422 shares in the last quarter. Financial Management Network Inc. grew its position in shares of Johnson & Johnson by 12.8% during the 2nd quarter. Financial Management Network Inc. now owns 3,015 shares of the company’s stock valued at $470,000 after purchasing an additional 341 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the period. Sawyer & Company Inc raised its position in shares of Johnson & Johnson by 2.4% in the second quarter. Sawyer & Company Inc now owns 20,948 shares of the company’s stock worth $3,200,000 after buying an additional 485 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its stake in Johnson & Johnson by 5.1% during the second quarter. Dynamic Advisor Solutions LLC now owns 51,196 shares of the company’s stock valued at $7,820,000 after buying an additional 2,507 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. UBS Group raised their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Barclays lifted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $177.87.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $176.98 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $426.23 billion, a P/E ratio of 18.93, a P/E/G ratio of 2.25 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The firm has a 50-day moving average of $172.09 and a 200-day moving average of $161.57.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.